|
|
|
|
|
Legal status
Patent not validated
| (51) | INT.CL. | A61K 31/4402 | |
| A61K 31/42 | |||
| A61P 3/06 | |||
| A61P 25/28 | |||
| A61P 9/00 |
| (11) | Number of the document | 1465627 |
| (13) | Kind of document | T |
| (96) | European patent application number | 02805961.6 |
| Date of filing the European patent application | 2002-12-18 | |
| (97) | Date of publication of the European application | 2004-10-13 |
| (45) | Date of publication and mention of the grant of the patent | 2006-03-08 |
| (46) | Date of publication of the claims translation |
| (86) | Number | PCT/US2002/040699 |
| Date | 2002-12-18 |
| (87) | Number | WO 2003/055485 |
| Date | 2003-07-10 |
| (30) | Number | Date | Country code |
| 345153 P | 2001-12-21 | US |
| (72) |
BROWN, Kathleen, Keating, GlaxoSmithKline, US
BAER, Philip, G., US
|
| (73) |
SMITHKLINE BEECHAM CORPORATION,
One Franklin Plaza, Philadelphia, PA 19101,
US
|
| (54) | DOSING REGIMEN FOR PPAR−GAMMA ACTIVATORS |
| DOSING REGIMEN FOR PPAR−GAMMA ACTIVATORS |